La clinique d'hématologie

info:eu-repo/semantics/publishe

Catheter-related intracardiac septic thrombosis [2]

SCOPUS: le.jinfo:eu-repo/semantics/publishe

Distal acquired demyelinating symmetric neuropathy associated with anti-GM1 antibodies: is this a CIDP variant?

Distal acquired demyelinating symmetric (DADS) neuropathy is clinically characterised by distal motor and sensory disturbances. Typically DADS does not respond or responds poorly to intravenous immunoglobulins (IVIg). We report the case of a 58-year-old patient who developed distal paraparesis. Serum electrophoresis demonstrated monoclonal IgM paraproteinemia having an anti-GM1 but no anti-MAG activity. Conduction velocities showed demyelinating pattern. Work-up excluded a lymphoproliferative disorder After IVIg treatment we observed a clinical and neurophysiological improvement. Regarding these peculiar findings, we suggest that DADS needs to be splitted in several forms determined among others by clinical, neurophysiological and antiganglioside profile and therapeutic response. We advocate to perform systematic antiganglioside antibodies assay additionnaly to anti-MAG when DADS is suspected in order to improve dysimmune neuropathies classification.Case ReportsJournal Articleinfo:eu-repo/semantics/publishe

The role of rituximab in adult's warm antibody autoimmune hemolytic anemia

Warm antibody hemolytic anemia is the most common form of autoimmune hemolytic anemia. When therapy is needed, corticosteroids remain the cornerstone of initial treatment but are able to cure only a minority of patients (less than 20%). Splenectomy is usually proposed when a second-line therapy is needed. This classical approach is now challenged by the use of rituximab both as second-line and as first-line therapy. Second-line treatment with rituximab leads to response rates similar to splenectomy (about 70%) but rituximab-induced responses seem less sustained. However, additional courses of rituximab are most often followed by responses, at the price of reasonable toxicity. In some major European centers, rituximab is now the preferred second-line therapy of warm antibody hemolytic anemia in adults, although no prospective study convincingly supports this attitude. A recent randomized study strongly suggests that in first-line treatment, rituximab combined with steroids is superior to monotherapy with steroids. If this finding is confirmed rituximab will emerge as a major component of the management of warm antibody hemolytic anemia not only after relapse but as soon as treatment is needed.status: publishe

Methotrexate-induced pneumonitis in rheumatoid arthritis: report of three cases

info:eu-repo/semantics/publishe

Antibiotic-lock technique for the treatment of central venous catheter infections [9]

SCOPUS: le.jinfo:eu-repo/semantics/publishe

DADS syndrome associated with anti-GM1 antibodies

info:eu-repo/semantics/publishe

Myorhythmia associated with Hodgkin's lymphoma.

Case ReportsLetterinfo:eu-repo/semantics/publishe

An illustrated case of altered cellular immunity after autologous stem cell transplantation.

We report an unusual association of T-cell lymphoma, autologous stem cell transplantation and Progressive Multifocal Leukoencephalopathy.Case ReportsJournal Articleinfo:eu-repo/semantics/publishe

Drépanocytose: Diagnostic et paramètres biologiques

SCOPUS: ar.jinfo:eu-repo/semantics/publishe